Next Article in Journal
Involvement of Up-Regulation of DR5 Expression and Down-Regulation of c-FLIP in Niclosamide-Mediated TRAIL Sensitization in Human Renal Carcinoma Caki Cells
Previous Article in Journal
Metal Chelating, Inhibitory DNA Damage, and Anti-Inflammatory Activities of Phenolics from Rambutan (Nephelium lappaceum) Peel and the Quantifications of Geraniin and Corilagin
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 23
Issue 9
10.3390/molecules23092265
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Iodide/H2O2 Catalyzed Intramolecular Oxidative Amination for the Synthesis of 3,2′-Pyrrolidinyl Spirooxindoles

by
Yu-Ting Gao
1,2,
Xiao-Yang Jin
1,2,
Qi Liu
1,2,
An-Di Liu
1,2,
Liang Cheng
1,2,*,
Dong Wang
1 and
Li Liu
1,2,*
1
Beijing National Laboratory for Molecular Sciences (BNLMS), CAS Key Laboratory of Molecular Recognition and Function, CAS Research/Education Center for Excellence in Molecular Sciences, Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, China
2
University of Chinese Academy of Sciences, Beijing 100049, China
*
Authors to whom correspondence should be addressed.
Molecules 2018, 23(9), 2265; https://doi.org/10.3390/molecules23092265
Submission received: 27 July 2018 / Revised: 21 August 2018 / Accepted: 24 August 2018 / Published: 5 September 2018
(This article belongs to the Section Organic Chemistry)
Browse Figures
Versions Notes

Abstract

:
An ammonium iodide/hydrogen peroxide-mediated intramolecular oxidative amination of 3-aminoalkyl-2-oxindoles was achieved, affording the corresponding 3,2′-pyrrolidinyl spirooxindoles and their 6- or 7-membered analogous in moderate to high yields. This metal-free procedure features very mild reaction conditions, non-toxicity and easily handled hydrogen peroxide as a clean oxidant.

1. Introduction

The 3,2′-pyrrolidinyl spirooxindoles and their 6- or 7- membered analogous are among one of the most important privileged structural units, whicH-Not only frequently appear in a plethora of biologically active oxindole alkaloids, but also in several pharmaceuticals [1,2,3,4,5,6,7,8,9,10,11,12,13]. As one of the most common such skeletons, 3,2′-pyrrolidinyl spirooxindoles shown a wide spectrum of notable bioactivities [14,15,16,17], such as local anesthetic and antimycobacterial effects, and binding to the MDM2 protein to interrupt its protein-protein interaction with TP53 (Figure 1).
Considering their potential pharmaceutical value, decades of research have introduced several synthetic methods to assemble this type of spirooxindole compounds. However, almost all published approaches are based on the powerful (3 + 2) cyclization to construct the five-membered pyrrolidinyl ring [18,19,20,21,22,23,24,25,26] (Scheme 1). For example, metal-catalyzed and organocatalytic cycloadditions of azomethine imines derived from isatins with a variety of dipolarophiles have been successfully developed (a,b-bond construction, pathway (1)). Alternatively, a nucleophilic attack of 1,3-ylides on isatin-3-imine derivatives also led to the formation of corresponding spirooxindoles (a,c-bond construction, pathway (2)). Despite the fact that these elegant one-step assemblies are capable of producing various spirooxindoles with molecular complexity and diversity, efficient and accessible methodologies towards these synthetic targets are still in high demand. The first intramolecular nucleophilic substitution of 3-halo-2-oxindoles providing a 3,2′-pyrrolidinyl-spirooxindole intermediate was reported by Cohen et al. almost 30 years ago (d-bond construction, pathway (3)) [27]. Unfortunately, almost no further development has been reported in the field of intramolecular amination. Very recently, Chen et al. described an annulation reaction of 3-bromo-2-oxindoles generating spirocyclic oxindoles, in which a cinchona alkaloid catalyzed amination was involved [27]. Thus, the potential application of simpler 3-H-2-oxindole precursors, which would provide the spirooxindole derivatives via a challenging intramolecular oxidative amination approach (pathway (4)), has not succeeded [28,29].
On the other hand, oxidative C–H/N–H coupling is a direct approach for the effective construction of C-N bonds [30,31,32,33,34,35]. However, most of the existing methods typically require the use of transition metals, which has hindered their practical application [30,31,32,33,34,35]. Therefore, the development of new C-N bond formation reactions under metal-free conditions is also in high demand [36,37,38,39,40,41]. Recently, the catalytic system with I− or I2 and a terminal oxidant has emerged as an environmentally benign oxidative system for a range of transformations, such as etherification, lactonization, and others [42,43,44,45,46,47,48,49,50,51]. Based on our continuing interest in the synthesis of 2-oxindole derivatives and the application of iodine/iodide catalysis [52,53,54,55,56,57], we herein report our progress in the TBAI/H2O2 catalyzed intramolecular oxidative amination of 3-aminoalkyl 2-oxindoles to give 3,2′-pyrrolidinyl-spirooxindoles and their 6/7-membered analogs [58,59,60,61,62].

2. Results and Discussion

To explore the possibility of the proposed intramolecular C-N bond formation process, our investigation began with a screening of several iodides to evaluate their catalytic activity under different reaction conditions (Table 1). The model reaction of (3-(benzylamino)propyl)-2-oxindole (1a) was firstly performed with the commonly used oxidant TBHP (entries 1–3). While the desired cyclization product 1′-benzylspiro[indoline-3,2′-pyrrolidin]-2-one (2a) could be obtained, only moderate yields were observed. To our delight, when H2O2 was used as the terminal oxidant, a slightly better result (62% yield) was obtained with TBAI as the optimal iodide source in CH3CN (entries 4–5). Subsequently, a survey of other solvents was carried out (entries 6–9). The results indicated that changing the solvent has a significant effect on the reaction. Among the solvents screened, toluene emerged as the most suitable medium in terms of high chemical yield (79%) and short reaction time (30 min) (entry 9).
The results with different substrates under the optimized conditions that probed the scope of this transformation are summarized in Scheme 2. A variety of substituted 3-aminopropanyl- 2-oxindoles 1b–n, including those bearing electron-withdrawing (F, Cl, Br, CF3) and electron-donating (CH3) substituents on the oxindole ring were examined. Gratifyingly, all of these substrates afforded the desired cyclization products 2b–n in good to high yields. It is noteworthy that the substituents on the amino group did not much influence the yield of the reaction and a good yield of 2n was obtained when an N-Ph substrate was used. However, for 2-oxindoles with longer aminoalkyl chains (compounds 2o–p), diminished yields were observed for the 6-membered and 7-membered spirooxindoles, respectively. The configuration of products was also confirmed by the X-ray crystallographic analysis of product 2k.
In order to demonstrate the synthetic utility of this methodology, we next performed the selective reduction of the amide by using borane. Spiro[indoline-3,2′-pyrrolidine] 3, a core structure found in several natural products and pharmaceutical agents [63], was obtained in 53% yield (Scheme 3).
Some control experiments were conducted in order to elucidate the mechanism. Previous reports [58,59,60,61,62] have suggested that a radical process was involved in iodide/oxidant catalyzed C-N bond formation. However, when a stoichiometric amount of radical inhibitors, like TEMPO, BHT and hydroquinone, was used, the cyclization of 1a proceeded smoothly and afforded the desired product 2a in comparable yields (Scheme 4), indicating a complete different pathway.
On the basis of the experimental results and recent studies [64,65,66], a possible stepwise mechanism is proposed (Scheme 5). First, two hypervalent iodine species, i.e., IO– and IO2− were likely generated by the oxidation of iodide with H2O2. Those hypervalent iodines then reacted with aminoalkyl 2-oxindoles 1 to form an iodoamino intermediate A, which was in equilibrium with its enolate B. The latter readily underwent an intramolecular substitution to afford the cyclization product 2, while releasing the iodide, which further underwent oxidation to regenerate the reactive hypervalent iodine species.
We had an initial predisposition toward using chiral iodide salts because of their easy preparation from enantiopure amines and well-known role as phase-transfer catalysts in asymmetric transformations [67,68,69]. Other catalytic use, particularly for asymmetric C-N bond formations, has been quite limited. Thus we prepared several cinchona alkaloid-based iodide salts 4a–c as chiral quaternary ammonium iodide salts, and tested their stereocontrol in this reaction with hydrogen peroxide as an environmentally benign oxidant (Scheme 6).
All those tested catalysts gave good results, with an average yield of 60%, however, no enantioselectivity was observed. Thus, a more detailed screening of other quaternary ammonium iodide salts may be needed for this transformation.

3. Materials and Methods

3.1. Chemicals and Instruments

Unless otherwise noted, all reagents were obtained from commercially suppliers and were used without further purification. All reactions were carried out under argon atmosphere using Schlenk techniques. Oxindoles 1 were obtained from commercially suppliers or prepared according to the literature procedures. TBAI were obtained from commercially suppliers. TLC analysis was performed on glass-baked silica plates and visualized with UV light. Column chromatography was performed on silica gel (200–300 mesh) using petroleum ether/ethyl acetate/ dichloromethane/methanol. 1H-, and 13C-NMR spectra were obtained on Bruker 300 MHz, 400 MHz or 500 MHz NMR spectrometer in the deuterated solvents indicated (Bruker, Billerica, MA, USA). Chemical shifts are reported in ppm from tetramethylsilane with the solvent resonance as the internal standard. The following abbreviations were used to designate chemical shift multiplicities: s = singlet, d = doublet, t = triplet, q = quartet, h = heptet, m = multiplet. All first-order splitting patterns were assigned on the basis of the appearance of the multiplet. Splitting patterns that could not be easily interpreted are designated as multiplet (m) or (br). Melting points were measured without correction on a Beijing Tech X-4 apparatus (Beijing Tech Instrument Co., Ltd., Beijing, China). IR spectra were recorded on a Nicolet 6700 FT-IR spectrometer (Thermo Fisher Scientific, Waltham, MA, USA). HRMS were obtained using electrospray ionization (ESI) mass spectrometer (Exactive, Thermo Fisher Scientific, Waltham, MA, USA).

3.2. Synthetic Procedures

3.2.1. General Procedure for Synthesis of 1

To a mixture of indolyl propionic acid [64] (10.0 mmol, 1.9 g) and triethylamine (20.0 mmol, 2.8 mL) in dichloromethane (70 mL) was added 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo [4,5-b]pyridinium 3-oxid hexafluorophosphate (12.0 mmol, 4.6 g) and benzylamine (12.0 mmol, 1.3 mL). The mixture was stirred at room temperature for 1 h and then diluted with dichloromethane (200 mL). The organic layer was washed by water (200 mL × 2), dried over anhydrous sodium sulfate and evaporated to afford the intermediate N-benzyl-3-(1H-indol-3-yl)propanamide without further purification. N-Benzyl-3-(1H-indol-3-yl)propanamide (8.0 mmol, 2.3 g) was dissolved in dry tetrahydrofuran (40 mL) under argon, and then a solution of lithium aluminum hydride (32.0 mmol, 12.8 mL, 2.5 M in THF) was added dropwise. The mixture was heated to reflux overnight and then cooled to room temperature. To the vigorously stirring mixture were added H2O (4 mL), 15% NaOH (4 mL), H2O (4 mL × 3) at 0 °C. After being stirred at 0 °C for another 10 min, the mixture was filtered through celite, the white filter cake was washed with methanol and the filtrate was concentrated in vacuum. The crude was purified by silica column chromatography (elute: dichloromethane /methanol 10/1, with 1% NH4OH) to afford the intermediate N-benzyl-3-(1H-indol-3-yl)- propan-1-amine[70] as a yellow oil. To the solution of N-benzyl-3-(1H-indol-3-yl)propan-1-amine (6.9 mmol,1.8 g) in dimethyl sulfoxide (20.7 mmol, 1.5 mL) and methanol (0.3 mL) was added concentrated hydrochloric acid (20.7 mmol, 1.7 mL) slowly at 0 °C. The resulting mixture was stirred at 50 °C for 5 h. After cooling to room temperature, the mixture was diluted with ethyl acetate (50 mL) and washed with H2O (50 mL). Aqueous phase was adjust to pH = 7 by ammonium hydroxide and extracted with ethyl acetate (50 mL × 2). The organic was dried over anhydrous sodium sulfate, evaporated and purified by silica column chromatography (elute: dichloromethane /methanol 10/1, with 1% NH4OH) to afford the desired product 3-(3-(benzylamino)propyl)indolin-2-one (1a) [71]. See the Supplementary Materials for the details.

3.2.2. General Procedure for the Synthesis of Compounds 2

To the mixture of oxindole 1 (0.10 mmol) and TBAI (20 mol%) in toluene (0.5 mL) was added 35% H2O2 (6 equiv.), the reaction mixture was stirred at room temperature until completion the reaction. After that time, the mixture was quenched by saturated sodium thiosulfate solution (1 mL) and diluted with dichloromethane (10 mL). The organic layer was washed by water (10 mL × 2), dried over anhydrous sodium sulfate and evaporated to afford the crude product. The crude was purified by silica column chromatography (elute: petroleum ether/ethyl acetate 2/1) to give the pure desired products 2.

3.3. Characterization Data

3-(3-(Benzylamino)propyl)indolin-2-one (1a): Yellow oil. 1H-NMR (300 MHz, CDCl3) δ 8.47 (br, 1H), 7.31–7.30 (m, 4H), 7.24–7.16 (m, 3H), 7.03–6.98 (t, J = 7.5, 1H), 6.86–6.84 (d, J = 7.5 Hz, 1H), 3.78 (s, 2H), 3.49–3.45 (t, J = 6.0 Hz, 1H), 2.68–2.63 (m, 2H), 2.49 (br, 1H), 2.05–1.98 (dd, J = 14.1, 8.1 Hz, 2H), 1.66–1.53 (m, 2H). 13C-NMR (126 MHz, DMSO-d6) δ 178.7, 142.7, 136.2, 129.4, 129.0, 128.3, 127.7, 127.6, 124.0, 121.2, 109.2, 51.3, 47.3, 44.7, 27.2, 23.6. IR νmax (KBr, film, cm−1): 3203, 3061, 2929, 2856, 1683, 1471, 751. HRMS (ESI): calcd for C18H21ON2+ [M + H]+: 281.1648, found: 281.1647.
3-(3-(benzylamino)propyl)-4-bromoindolin-2-one (1b): Pink solid, m.p. 83–85 °C. 1H-NMR (300 MHz, DMSO-d6) δ 10.70 (s, 1H), 8.56 (br, 1H), 7.43–7.38 (m, 5H), 7.16–7.14 (d, J = 5.4 Hz, 2H), 6.86–6.84 (d, J = 3.9 Hz, 1H), 4.01 (s, 2H), 3.60 (s, 1H), 2.84–2.79 (t, J = 7.8 Hz, 2H), 2.21–2.18 (m, 1H), 2.02–1.98 (m, 1H), 1.42–1.37 (m, 2H). 13C-NMR (126 MHz, DMSO-d6) δ 177.3, 144.8, 133.0, 130.0, 129.8, 128.54, 128.49, 127.8, 124.6, 118.4, 108.7, 50.2, 46.5, 46.2, 24.6, 21.4. IR νmax (KBr, film, cm−1): 3360, 2920, 2848, 1698, 1458, 1019, 699. HRMS (ESI): calcd for C18H20ON2Br+ [M + H]+: 359.0754, found: 359.0750.
3-(3-(benzylamino)propyl)-5-chloroindolin-2-one (1c): Orange solid, m.p. 89–91 °C. 1H-NMR (500 MHz, DMSO-d6) δ 10.59 (s, 1H), 8.81 (br, 1H), 7.51–7.48 (m, 2H), 7.39–7.36 (m, 4H), 7.24–7.21 (t, J = 8.0 Hz, 1H), 6.85–6.82 (m,1H), 4.02 (s, 2H), 3.53–3.51 (t, J = 5.5 Hz, 1H), 2.83–2.80 (m, 2H), 1.89–1.85 (m, 2H), 1.60–1.58 (m, 2H). 13C-NMR (126 MHz, DMSO-d6) δ 178.2, 141.7, 133.0, 131.5, 129.8, 128.6, 128.5, 127.5, 125.4, 124.3, 110.6, 50.3, 46.5, 44.8, 26.6, 22.2. IR νmax (KBr, film, cm−1): 3446, 2920, 2849, 1702, 1478, 699. HRMS (ESI): calcd for C18H20ON2Cl+ [M + H]+: 315.1259, found: 315.1257.
3-(3-(Benzylamino)propyl)-6-fluoroindolin-2-one (1d): Pink solid, m.p. 81–83 °C. 1H-NMR (500 MHz, DMSO-d6) δ 10.62 (s, 1H), 9.05 (br, 1H), 7.52–7.51 (m, 2H), 7.40 (m, 1H), 7.39–7.38 (m, 2H), 7.30–7.26 (m, 1H), 6.77–6.74 (m, 1H), 6.66–6.64 (m, 1H), 4.04 (s, 2H), 3.47–3.45 (t, J = 5.5 Hz, 1H), 2.85–2.82 (t, J = 6.5 Hz, 2H), 1.91–1.82 (m, 2H), 1.64–1.63 (m, 2H). 13C-NMR (126 MHz, DMSO-d6) δ 178.9, 163.0, 161.0, 144.3, 144.2, 132.5, 129.9, 128.7, 128.5, 125.33, 125.26, 125.02, 125.00, 107.3, 107.1, 97.5, 97.3, 50.1, 46.4, 44.0, 26.9, 22.0. 19F NMR (377 MHz, DMSO-d6) −113.9(s). IR νmax (KBr, film, cm−1): 3359, 3195, 2920, 2849, 1702, 1469, 1340. HRMS (ESI): calcd for C18H20ON2F+ [M + H]+: 299.1554, found: 299.1554.
3-(3-(Benzylamino)propyl)-6-chloroindolin-2-one (1e): Orange solid, m.p. 89–91 °C. 1H-NMR (300 MHz, DMSO-d6) δ 10.64 (s, 1H), 9.07 (br, 1H), 7.53–7.50 (m, 2H), 7.43–7.38 (m, 3H), 7.30–7.27 (m, 1H), 7.01–6.87 (dd, J = 7.8, 1.5 Hz, 1H), 6.87–6.86 (d, J = 1.5 Hz, 1H), 4.04 (s, 2H), 3.50–3.47 (t, J = 5.7 Hz, 1H), 2.85–2.80 (t, J = 7.8 Hz, 2H), 1.91–1.81 (m, 2H), 1.65–1.63 (m, 2H). 13C-NMR (75 MHz, DMSO) δ 178.4, 144.3, 132.5, 131.9, 129.8, 128.6, 128.5, 128.1, 125.5, 120.8, 109.3, 50.0, 46.3, 44.1, 26.7, 21.9. IR νmax (KBr, film, cm−1): 3360, 3188, 2920, 2848, 1703, 1486, 749. HRMS (ESI): calcd for C18H20ON2Cl+ [M + H]+: 315.1259, found: 315.1258.
3-(3-(Benzylamino)propyl)-7-methylindolin-2-one (1f): White solid, m.p. 202–204 °C. 1H-NMR (300 MHz, DMSO-d6) δ 10.45 (s, 1H), 9.00 (br, 1H), 7.51–7.48 (m, 2H), 7.45–7.40(m, 3H), 7.10–7.07 (d, J = 7.2 Hz, 1H), 7.01–6.98 (d, J = 7.8 Hz, 1H), 6.90–6.85 (t, J = 7.5 Hz, 1H), 4.07 (s, 2H), 3.49–3.48 (t, J = 5.4 Hz, 1H), 2.90–2.85 (m, 2H), 2.19 (s, 3H), 1.91–1.82 (m, 2H), 1.68–1.61 (m, 2H). 13C-NMR (126 MHz, DMSO-d6) δ 179.0, 141.3, 132.2, 129.9, 129.0, 128.81, 128.78, 128.6, 121.3, 118.5, 50.1, 46.5, 44.8, 26.8, 22.0, 16.5. IR νmax (KBr, film, cm−1): 3392, 2946, 2838, 1702, 1458, 694. HRMS (ESI): calcd for C19H23ON2+ [M + H]+: 295.1805, found: 295.1804.
3-(3-((4-Methylbenzyl)amino)propyl)indolin-2-one (1g): Yellow oil. 1H-NMR (300 MHz, CDCl3) δ 8.04 (br, 1H), 7.22–7.10 (m, 6H), 7.03–6.98 (t, J = 7.2 Hz, 1H), 6.85–6.83 (m, 1H), 3.71 (s, 2H), 3.49–3.46 (t, J = 6.0 Hz, 1H), 2.65–2.60 (t, J = 7.2 Hz, 2H), 2.32 (s, 3H), 2.02–1.97 (m, 2H), 1.72 (br, 1H), 1.64–1.52 (m, 2H). 13C-NMR (126 MHz, CDCl3) δ 180.2, 141.6, 136.9, 136.5, 129.5, 129.1, 128.1, 127.8, 124.1, 122.2, 109.6, 53.5, 48.9, 45.7, 28.1, 26.0, 21.1. IR νmax (KBr, film, cm−1): 3204, 3022, 2923, 2857, 1706, 1620, 1486, 751. HRMS (ESI): calcd for C19H23ON2+ [M + H]+: 295.1805, found: 295.1804.
3-(3-((4-Methoxybenzyl)amino)propyl)indolin-2-one (1h): Yellow oil. 1H-NMR (300 MHz, DMSO-d6) δ 10.34 (br, 1H), 7.23–7.13 (m, 4H), 6.96–6.91 (t, J = 7.5 Hz, 1H), 6.85–6.81 (m, 3H), 3.71 (s, 3H), 3.56 (s, 2H), 3.42–3.38 (t, J = 5.7 Hz, 1H), 2.97 (br, 1H), 2.46–2.41(t, J = 7.2 Hz, 2H), 1.89–1.79 (m, 2H), 1.43–1.37 (m, 2H). 13C-NMR (126 MHz, DMSO-d6) δ 178.9, 158.0, 142.8, 132.6, 129.7, 129.1, 127.5, 123.9, 121.2, 113.4, 109.1, 54.9, 52.2, 48.3, 45.0, 27.7, 25.5. IR νmax (KBr, film, cm−1): 3197, 2933, 2835, 1698, 1471, 1177, 751. HRMS (ESI): calcd for C19H23O2N2+ [M + H]+: 311.1765, found: 311.1747.
3-(3-((4-Fluorobenzyl)amino)propyl)indolin-2-one (1i): Yellow solid, m.p. 101–103 °C 1H-NMR (300 MHz, DMSO-d6) δ 10.42 (s, 1H), 8.86 (br, 1H), 7.57–7.52 (m, 2H), 7.28–7.15 (m, 4H), 6.98–6.93 (t, J = 7.5 Hz, 1H), 6.84–6.82 (d, J = 7.8 Hz, 1H), 4.05 (s, 2H), 3.50–3.48 (t, J = 5.7 Hz, 1H), 2.87–2.82 (t, J = 7.8 Hz, 2H), 1.89–1.82 (m, 2H), 1.67–1.59 (m, 2H). 13C-NMR (101 MHz, DMSO-d6) δ 178.5, 163.4, 161.0, 142.7, 132.3, 132.3, 129.2, 128.6, 127.6, 124.0, 121.2, 115.4, 115.2, 109.2, 49.1, 46.2, 44.5, 26.9, 22.0. 19F NMR (377 MHz, DMSO-d6) δ −113.9(s). IR νmax (KBr, film, cm−1): 3361, 2920, 2849, 1703, 1471, 1226, 751. HRMS (ESI): calcd for C18H20ON2F+ [M + H]+: 299.1554, found: 299.1553.
3-(3-((4-Chlorobenzyl)amino)propyl)indolin-2-one (1j): Yellow oil. 1H-NMR (300 MHz, CDCl3) δ 8.76 (br, 1H), 7.31–7.28 (m, 1H), 7.25–7.17(m, 5H), 7.03–6.98 (t, J = 7.5 Hz, 1H), 6.87–6.84 (d, J = 7.8 Hz, 1H), 3.72 (s, 2H), 3.49–3.45 (t, J = 5.7 Hz, 1H), 2.64–2.59 (t, J = 7.2 Hz, 2H), 2.24–2.19 (m, 1H), 2.04–1.97 (dd, J = 14.1, 7.8 Hz, 2H), 1.62–1.51 (m, 2H). 13C-NMR (126 MHz, CDCl3) δ 180.2, 141.6, 138.3, 132.7, 129.5, 129.4, 128.5, 127.9, 124.1, 122.3, 109.7, 53.0, 48.7, 45.7, 28.0, 25.9. IR νmax (KBr, film, cm−1): 3200, 2932, 1714, 1471, 1015, 751. HRMS (ESI): calcd for C18H20ON2Cl+ [M + H]+: 315.1259, found: 315.1256.
3-(3-((4-Bromobenzyl)amino)propyl)indolin-2-one (1k): Yellow solid, m.p. 102–104 °C. 1H-NMR (300 MHz, DMSO-d6) δ 10.41 (s, 1H), 8.33 (br, 1H), 7.60–7.58 (d, J = 8.1 Hz, 2H), 7.44–7.41 (d, J = 8.1 Hz, 2H), 7.27–7.24 (d, J = 7.2 Hz, 1H), 7.20–7.15 (t, J = 7.8 Hz, 1H), 6.97–6.92 (t, J = 7.5 Hz, 1H), 6.84–6.81 (d, J = 7.8 Hz, 1H), 3.96 (s, 2H), 3.48–3.44 (t, J = 5.7 Hz, 1H), 2.80–2.74 (t, J = 7.5 Hz, 2H), 1.91–1.80 (m, 2H), 1.64–1.55 (m, 2H). 13C-NMR (75 MHz, DMSO-d6) δ 178.6, 142.7, 131.8, 131.3, 129.3, 127.7, 124.0, 121.6, 121.2, 109.2, 49.8, 46.8, 44.7, 26.9, 22.7. IR νmax (KBr, film, cm−1): 3366, 3197, 2922, 2850, 1702, 1622, 1471, 753. HRMS (ESI): calcd for C18H20ON2Br+ [M + H]+: 359.0754, found: 359.0740.
6-Fluoro-3-(3-((4-(trifluoromethyl)benzyl)amino)propyl)indolin-2-one (1l): Orange oil. 1H-NMR (300 MHz, DMSO-d6) δ 10.56 (br, 1H), 7.69–7.66 (d, J = 7.8 Hz, 2H), 7.58–7.55 (d, J = 7.8 Hz, 2H), 7.30–7.25 (m, 1H), 6.81–6.67 (m, 2H), 3.77 (s, 2H), 3.48–3.44 (t, J = 6.3Hz, 1H), 2.56 (s, 1H), 1.95–1.87 (m, 3H), 1.49–1.41 (m, 3H). 13C-NMR (126 MHz, DMSO-d6) δ 179.8, 163.3, 161.4, 146.5, 144.8, 144.7, 128.9, 125.9, 125.6, 125.5, 125.30, 125.27, 107.7, 107.5, 97.9, 97.7, 52.8, 49.0, 45.0, 28.1, 26.0. 19F NMR (377 MHz, DMSO-d6) δ −60.86(s), −113.93 (s). IR νmax (KBr, film, cm−1): 3633, 2952, 2855, 1717, 1558, 1329, 1020, 849, 737. HRMS (ESI): calcd for C19H19ON2F4+ [M + H]+: 367.1428, found: 367.1422.
6-Chloro-3-(3-((4-(trifluoromethyl)benzyl)amino)propyl)indolin-2-one (1m): Orange oil. 1H-NMR (300 MHz, DMSO-d6) δ 10.57 (br, 1H), 7.71–7.68 (d, J = 7.8 Hz, 2H), 7.58–7.56 (d, J = 7.8 Hz, 2H), 7.30–7.28 (m, 1H), 7.05–7.02 (m, 1H), 6.89 (s, 1H), 3.77 (s, 2H), 3.52–3.48 (t, J = 5.7 Hz, 1H), 2.57 (s, 1H), 1.97–1.86 (m, 3H), 1.50–1.38 (m, 3H). 13C-NMR (126 MHz, DMSO-d6) δ 178.9, 146.1, 144.3, 131.8, 128.6, 128.4, 125.3, 124.83, 124.80, 120.8, 109.2, 52.3, 48.5, 44.6, 27.5, 25.5. 19F NMR (377 MHz, DMSO-d6) δ −60.79 (s). IR νmax (KBr, film, cm−1): 3419, 3181, 2952, 2800, 1704, 1619, 1326, 1127, 1068, 737. HRMS (ESI): calcd for C19H19ON2ClF3+ [M + H]+: 382.1133, found: 383.1126.
3-(3-(Phenylamino)propyl)indolin-2-one (1n): Pale yellow solid, m.p. 105–107 °C. 1H-NMR (500 MHz, CDCl3) δ 8.87 (s, 1H), 7.24–7.22 (m, 2H), 7.17–7.14 (t, J = 7.5 Hz, 2H), 7.06–7.03 (t, J = 7.5 Hz, 1H), 6.93–6.91 (d, J = 8.5 Hz, 1H), 6.70–6.67 (m, 1H), 6.57–6.56 (d, J = 8.5 Hz, 2H), 3.67 (br, 1H), 3.56–3.54 (t, J = 5.5 Hz, 2H), 3.14–3.11 (t, J = 7.0 Hz, 2H), 2.13–2.09 (m, 2H), 1.77–1.66 (m, 2H). 13C-NMR (126 MHz, CDCl3) δ 180.4, 148.2, 141.6, 129.3, 129.2, 128.0, 124.0, 122.4, 117.2, 112.7, 109.8, 45.7, 43.7, 27.9, 25.7. IR νmax (KBr, film, cm−1): 3368, 3210, 2925, 2855, 1707, 1602, 1471, 749. HRMS (ESI): calcd for C17H19ON2+ [M + H]+: 267.1492, found: 267.1494.
3-(4-(Benzylamino)butyl)indolin-2-one (1o): Pale yellow solid, m.p. 172–173 °C. 1H-NMR (300 MHz, DMSO-d6) δ 10.41 (s, 1H), 8.66 (br, 1H), 7.52–7.50 (m, 2H), 7.38–7.36 (m, 3H), 7.26–7.24 (d, J = 7.5 Hz, 1H),7.19–7.14 (t, J = 7.5 Hz, 1H), 6.96–6.91 (t, J = 7.2 Hz, 1H), 6.84–6.82 (d, J = 7.5 Hz, 1H), 3.99 (s, 2H), 3.43–3.39 (m, 1H), 2.77–2.71 (t, J = 7.5 Hz, 2H), 1.85–1.76 (m, 2H), 1.65–1.60 (m, 2H), 1.32–1.24 (m, 2H). 13C-NMR (101 MHz, DMSO-d6) δ 178.7, 142.7, 133.3, 129.7, 129.5, 128.42, 128.38, 127.5, 123.9, 121.1, 109.1, 50.2, 46.4, 44.9, 29.5, 25.8, 22.6. IR νmax (KBr, film, cm−1): 3359, 2920, 2849, 1702, 1472, 751. HRMS (ESI): calcd for C19H23ON2+ [M + H]+: 295.1805, found: 295.1802.
3-(5-(Benzylamino)pentyl)indolin-2-one (1p): Yellow oil. 1H-NMR (300 MHz, CDCl3) δ 8.47 (br, 1H), 7.34–7.28 (m, 5H), 7.24–7.20 (m, 2H), 7.05–7.00 (m, 1H), 6.90–6.88 (d, J = 8.1 Hz, 1H), 3.80 (s, 2H), 3.49–3.45 (t, J = 6.0 Hz, 1H), 2.65–2.60 (t, J = 6.9 Hz, 2H), 2.22 (br, 1H), 2.00–1.95 (m, 2H), 1.55–1.48 (m, 2H), 1.45–1.36 (m, 4H). 13C-NMR (126 MHz, CDCl3) δ 180.2, 141.5, 139.7, 129.7, 128.4, 128.2, 127.8, 127.0, 124.1, 122.2, 109.6, 53.8, 49.0, 45.9, 30.4, 29.5, 27.2, 25.5. IR νmax (KBr, film, cm−1): 3197, 3061, 2830, 2856, 1683, 1506, 1471, 749. HRMS (ESI): calcd for C20H25ON2+ [M + H]+: 309.1961, found: 309.1959.
1′-Benzylspiro[indoline-3,2′-pyrrolidin]-2-one (2a): White solid, 21.9 mg (from 0.10 mmol), 79% yield, m.p. 154–156 °C. 1H-NMR (500 MHz, DMSO-d6) δ 10.28 (s, 1H), 7.35–7.33 (d, J = 7.5 Hz, 1H), 7.26–7.22 (m, 2H), 7.20–7.18 (m, 4H), 7.03–7.00 (t, J = 7.5 Hz, 1H), 6.80–6.79 (d, J = 7.5 Hz, 1H), 3.31–3.25 (m, 2H), 2.98–2.91 (m, 2H), 2.14–2.06 (m, 2H), 2.04–1.98 (m, 2H). 13C-NMR (126 MHz, DMSO-d6) δ 179.7, 142.4, 139.3, 130.7, 128.7, 128.1, 127.9, 126.8, 123.8, 121.9, 109.4, 70.8, 53.1, 50.4, 35.8, 21.7. IR νmax (KBr, film, cm−1): 3207, 3061, 3028, 2925, 2852, 1706, 1620, 1470, 749. HRMS (ESI): calcd for C18H17ON2− [M − H]−: 277.1364, found: 277.1364.
1′-Benzyl-4-bromospiro[indoline-3,2′-pyrrolidin]-2-one (2b): White solid, 17.6 mg (from 0.10 mmol), 49% yield, m.p. 169–171 °C. 1H-NMR (500 MHz, CDCl3) δ 8.74 (s, 1H), 7.32–7.31 (d, J = 7.5 Hz, 2H), 7.26–7.15 (m, 4H), 7.08–7.05 (m, 1H), 6.81–6.80 (dd, J = 7.5, 1.0 Hz, 1H), 3.59–3.49 (m, 2H), 3.17–3.10 (m, 2H), 2.68–2.63 (m, 1H), 2.25–2.18 (m, 3H). 13C-NMR (126 MHz, CDCl3) δ 181.3, 143.2, 139.5, 130.1, 128.7, 128.5, 128.0, 127.4, 126.8, 119.9, 108.9, 72.5, 53.4, 51.1, 32.8, 23.1. IR νmax (KBr, film, cm−1): 3213, 3086, 3027, 2964, 2831, 1717, 1613, 1447, 736. HRMS (ESI): calcd for C18H18ON2Br+ [M + H]+: 357.0597, found: 354.0594.
1′-Benzyl-5-chlorospiro[indoline-3,2′-pyrrolidin]-2-one (2c): White solid, 14.3 mg (from 0.10 mmol), 46% yield, m.p. 149–151 °C. 1H-NMR (500 MHz, CDCl3) δ 8.47 (s, 1H), 7.34 (s, 1H), 7.25–7.19 (m, 6H), 6.79–6.78 (d, J = 8.0 Hz, 1H), 3.52–3.45 (m, 2H), 3.18–3.13 (m, 1H), 3.10–3.07 (m, 1H), 2.35–2.31 (m, 1H), 2.24–2.21 (m, 1H), 2.17–2.08 (m, 2H). 13C-NMR (126 MHz, CDCl3) δ 181.2, 139.5, 138.9, 133.4, 128.6, 128.5, 128.2, 128.1, 127.0, 124.6, 110.8, 71.7, 53.9, 51.4, 37.0, 22.3. IR νmax (KBr, film, cm−1): 3213, 3063, 3029, 2963, 2840, 1717, 1619, 1475, 733. HRMS (ESI): calcd for C18H18ON2Br+ [M + H]+: 313.1102, found: 313.1102.
1′-Benzyl-6-fluorospiro[indoline-3,2′-pyrrolidin]-2-one (2d): White solid, 15.3 mg (from 0.10 mmol), 52% yield, m.p. 141–143 °C. 1H-NMR (300 MHz, CDCl3) δ 8.88 (s, 1H), 7.33–7.29 (m, 1H), 7.23–7.15 (m, 5H), 6.81–6.74 (m, 1H), 6.65–6.62 (dd, J = 14.5, 2.1 Hz, 1H), 3.52–3.41 (m, 2H), 3.22–3.06 (m, 2H), 2.35–2.04 (m, 4H). 13C-NMR (126 MHz, CDCl3) δ 182.1, 164.1, 162.2, 142.5, 142.4, 139.0, 128.5, 128.1, 126.9, 126.7, 126.6, 125.3, 125.2, 109.2, 109.0, 98.7, 98.4, 71.2, 53.8, 51.2, 36.7, 22.1. 19F NMR (377 MHz, CDCl3) δ −111.7 (s). IR νmax (KBr, film, cm−1): 3226, 3063, 3029, 2965, 2836, 1717, 1622, 1456, 733. HRMS (ESI): calcd for C18H18ON2F+ [M + H]+: 297.1398, found: 297.1400.
1′-Benzyl-6-chlorospiro[indoline-3,2′-pyrrolidin]-2-one (2e): White solid, 19.0 mg (from 0.10 mmol), 61% yield, m.p. 170–172 °C. 1H-NMR (500 MHz, CDCl3) δ 8.67 (s, 1H), 7.30–7.28 (m, 1H), 7.25–7.21 (m, 2H), 7.20–7.18 (m, 3H), 7.08–7.05 (m, 1H), 6.89 (s, 1H), 3.50–3.42 (m, 2H), 3.19–3.14 (m, 1H), 3.10–3.06 (m, 1H), 2.35–2.29 (m, 1H), 2.27–2.22 (m, 1H), 2.17–2.07 (m, 2H). 13C-NMR (126 MHz, CDCl3) δ 181.6, 142.2, 139.0, 134.3, 129.8, 128.5, 128.1, 127.0, 125.2, 122.8, 110.5, 71.3, 53.9, 51.2, 36.7, 22.2. IR νmax (KBr, film, cm−1): 3232, 3064, 3029, 2965, 2834, 1717, 1615, 1455, 732. HRMS (ESI): calcd for C18H18ON2Cl + [M + H]+: 313.1102, found: 313.1101.
1′-Benzyl-7-methylspiro[indoline-3,2′-pyrrolidin]-2-one (2f): White solid, 20.5 mg (from 0.10 mmol), 70% yield, m.p. 148–150 °C. 1H-NMR (500 MHz, CDCl3) δ 8.83 (s, 1H), 7.23–7.16 (m, 6H), 7.07–7.05 (m, 1H), 7.03–7.00 (m, 1H), 3.51–3.42 (m, 2H), 3.20–3.15 (m, 1H), 3.10–3.06 (m, 1H), 2.35–2.31 (m, 1H), 2.29 (s, 3H), 2.27–2.21 (m, 1H), 2.19–2.14 (m, 1H), 2.11–2.08 (m, 1H). 13C-NMR (126 MHz, CDCl3) δ 182.0, 139.9, 139.4, 130.9, 130.0, 128.5, 128.0, 126.8, 122.7, 121.5, 119.0, 72.0, 54.0, 51.2, 36.7, 22.2, 16.2. IR νmax (KBr, film, cm−1): 3280, 3061, 3028, 2964, 2837, 1704, 1627, 1458, 732. HRMS (ESI): calcd for C19H21ON2+ [M + H]+: 293.1648, found: 293.1648.
1′-(4-Methylbenzyl)spiro[indoline-3,2′-pyrrolidin]-2-one (2g): White solid, 22.7 mg (from 0.10 mmol), 79% yield, m.p. 96–98 °C. 1H-NMR (500 MHz, CDCl3) δ 9.03 (s, 1H), 7.37–7.36 (d, J = 7.0 Hz, 1H), 7.23–7.20 (t, J = 8.0 Hz, 1H), 7.09–7.06 (m, 3H), 7.03–7.01 (m, 2H), 6.89–6.87 (d, J = 8.0 Hz, 1H), 3.45–3.38 (m, 2H), 3.20–3.15 (m, 1H), 3.09–3.05 (m, 1H), 2.35–2.30 (m, 1H), 2.26 (s, 3H), 2.22–2.04 (m, 3H). 13C-NMR (126 MHz, CDCl3) δ 182.0, 141.3, 136.3, 136.2, 131.4, 128.7, 128.6, 128.4, 124.1, 122.7, 109.9, 71.7, 53.5, 51.1, 36.6, 22.2, 21.0. IR νmax (KBr, film, cm−1): 3215, 3025, 2971, 2830, 1706, 1620, 1471, 750. HRMS (ESI): calcd for C19H21ON2+ [M + H]+: 293.1648, found: 293.1647.
1′-(4-Methoxybenzyl)spiro[indoline-3,2′-pyrrolidin]-2-one (2h): White solid, 17.1 mg (from 0.10 mmol), 56% yield, m.p. 135–137 °C. 1H-NMR (500 MHz, CDCl3) δ 8.52 (s, 1H), 7.37–7.36 (d, J = 7.0 Hz, 1H), 7.24–7.21 (t, J = 7.5 Hz, 1H), 7.10–7.07 (m, 3H), 6.87–6.85 (d, J = 8.0 Hz, 1H), 6.77–6.75 (d, J = 8.0 Hz, 2H), 3.73 (s, 3H), 3.44–3.36 (m, 2H), 3.20–3.15 (m, 1H), 3.09–3.05 (m, 1H), 2.35–2.30 (m, 1H), 2.24–2.21 (m, 1H), 2.18–2.07 (m, 2H). 13C-NMR (126 MHz, CDCl3) δ 181.6, 158.5, 141.2, 131.5, 131.4, 129.7, 128.6, 124.2, 122.7, 113.4, 109.8, 71.5, 55.1, 53.3, 51.2, 36.7, 22.2. IR νmax (KBr, film, cm−1): 3251, 2962, 2834, 1700, 1622, 1471, 751. HRMS (ESI): calcd for C19H19ON2− [M − H]−: 307.1452, found: 307.1454.
1′-(4-Fluorobenzyl)spiro[indoline-3,2′-pyrrolidin]-2-one (2i): White solid, 10.9 mg (from 0.10 mmol), 37% yield, m.p. 126–127 °C. 1H-NMR (500 MHz, CDCl3) δ 7.89 (s, 1H), 7.36–7.35 (d, J = 7.0 Hz, 1H), 7.24–7.21 (td, J = 7.5, 1.0 Hz, 1H), 7.16–7.13 (m, 2H), 7.10–7.07 (t, J = 7.5 Hz, 1H), 6.92–6.88 (m, 2H), 6.84–6.82 (d, J = 7.5 Hz, 1H), 3.46–3.39 (m, 2H), 3.17–3.13 (m, 1H), 3.07–3.03 (m, 1H), 2.35–2.30 (m, 1H), 2.28–2.20 (m, 1H), 2.18–2.13 (m, 1H), 2.11–2.06 (m, 1H). 13C-NMR (126 MHz, CDCl3) δ 181.6, 162.8, 160.9, 141.1, 134.9, 131.3, 130.1, 130.0, 128.7, 124.1, 122.8, 114.8, 114.7, 109.9, 71.5, 53.2, 51.3, 36.7, 22.2. 19F NMR (377 MHz, CDCl3) δ −116.1 (s). IR νmax (KBr, film, cm−1): 3213, 3086, 2964, 2836, 1717, 1622, 1471, 750. HRMS (ESI): calcd for C18H18ON2F+ [M + H]+: 297.1398, found: 297.1395.
1′-(4-Chlorobenzyl)spiro[indoline-3,2′-pyrrolidin]-2-one (2j): White solid, 23.3 mg (from 0.10 mmol), 74% yield, m.p. 140–142 °C. 1H-NMR (500 MHz, CDCl3) δ 8.54 (s, 1H), 7.36–7.34 (d, J = 7.5 Hz, 1H), 7.25–7.21 (m, 1H), 7.19–7.18 (m, 2H), 7.13–7.12 (m, 2H), 7.10–7.07 (td, J = 7.5, 0.5 Hz, 1H), 6.88–6.86 (d, J = 7.5 Hz, 1H), 3.46–3.39 (m, 2H), 3.17–3.13 (m, 1H), 3.07–3.04 (m, 1H), 2.36–2.31 (m, 1H), 2.28–2.21 (m, 1H), 2.19–2.13 (m, 1H), 2.12–2.04 (m, 1H). 13C-NMR (126 MHz, CDCl3) δ 181.5, 141.1, 137.8, 132.5, 131.2, 129.8, 128.7, 128.1, 124.1, 122.7, 109.9, 71.5, 53.2, 51.3, 36.7, 22.2. IR νmax (KBr, film, cm−1): 3212, 2925, 2849, 1705, 1622, 1471, 750. HRMS (ESI): calcd for C18H18ON2Cl+ [M + H]+: 313.1102, found: 313.1099.
1′-(4-Bromobenzyl)spiro[indoline-3,2′-pyrrolidin]-2-one (2k): White solid, 19.6 mg (from 0.10 mmol), 55% yield, m.p. 140–142 °C. 1H-NMR (500 MHz, CDCl3) δ 8.36 (s, 1H), 7.35–7.33 (m, 3H), 7.24–7.21 (t, J = 7.5 Hz, 1H), 7.09–7.07 (m, 3H), 6.86–6.85 (d, J = 8.0 Hz, 1H), 3.43–3.38 (m, 2H), 3.17–3.12 (q, J = 7.5 Hz, 1H), 3.07–3.03 (m, 1H), 2.35–2.30 (m, 1H), 2.28–2.20 (m, 1H), 2.19–2.13 (m, 1H), 2.12–2.08 (m, 1H). 13C-NMR (126 MHz, CDCl3) δ 181.3, 141.1, 138.3, 131.2, 131.1, 130.2, 128.7, 124.2, 122.9, 120.6, 109.8, 71.5, 53.3, 51.3, 36.7, 22.3. IR νmax (KBr, film, cm−1): 3216, 3090, 2925, 2851, 1706, 1621, 1470, 750. HRMS (ESI): calcd for C18H18ON2Br+ [M + H]+: 357.0597, found: 357.0594.
6-Fluoro-1′-(4-(trifluoromethyl)benzyl)spiro[indoline-3,2′-pyrrolidin]-2-one (2l): Syrup, 20.5 mg (from 0.10 mmol), 56% yield. 1H-NMR (300 MHz, CDCl3) δ 8.84 (br, 1H), 7.50–7.47 (d, J = 7.8 Hz, 2H), 7.33–7.27 (m, 3H), 6.79–6.74 (m, 1H), 6.65–6.62 (mz, 1H), 3.51 (s, 2H), 3.19–3.04 (m, 2H), 2.35–2.10 (m, 4H). 13C-NMR (126 MHz, CDCl3) δ 181.9, 164.2, 162.23, 143.2, 142.5, 142.4, 129.4, 129.1, 128.8, 128.6, 126.38, 126.36, 125.5, 125.3, 125.2, 125.1, 125.03, 125.00, 124.97, 109.4, 109.2, 98.7, 98.5, 713, 53.4, 51.3, 36.7, 22.2. 19F NMR (377 MHz, CDCl3) δ −62.4 (s), −111.3 (s). IR νmax (KBr, film, cm−1): 3235, 2964, 2842, 1717, 1619, 1458, 1326, 1125, 1067, 1019, 810. HRMS (ESI): calcd for C19H17ON2F4+ [M + H]+: 365.1272, found: 365.1266.
6-Chloro-1′-(4-(trifluoromethyl)benzyl)spiro[indoline-3,2′-pyrrolidin]-2-one (2m): Syrup, 19.7 mg (from 0.10 mmol), 52% yield. 1H-NMR (300 MHz, CDCl3) δ 8.75 (br, 1H), 7.51–7.47 (m, 2H), 7.33–7.27 (m, 3H), 7.09–7.06 (m, 1H), 6.91–6.90 (m, 1H), 3.51 (s, 2H), 3.17–3.07 (m, 2H), 2.33–2.13 (m, 4H). 13C-NMR (126 MHz, CDCl3) δ 181.5, 143.2, 142.2, 134.5, 129.5, 128.6, 125.09, 125.05, 125.0, 123.0, 110.6, 71.3, 53.5, 51.3, 36.7, 22.3. 19F NMR (377 MHz, CDCl3) δ −62.4 (s). IR νmax (KBr, film, cm−1):3232, 2963, 2938, 1713, 1616, 1486, 1325, 1124, 1066, 812. HRMS (ESI): calcd for C19H17ON2ClF3+ [M + H]+: 381.0976, found: 381.0971.
1′-Phenylspiro[indoline-3,2′-pyrrolidin]-2-one (2n): White solid, 19.0 mg (from 0.10 mmol), 72% yield, m.p. 140–142 °C. 1H-NMR (400 MHz, CDCl3) δ 9.03 (s, 1H), 7.22–7.18 (td, J = 7.6, 0.8 Hz, 1H), 7.13–7.11 (d, J = 7.6 Hz, 1H), 7.05–7.01 (m, 2H), 7.00–6.96 (m, 1H), 6.89–6.86 (d, J = 8.0 Hz, 1H), 6.63–6.59 (t, J = 7.2 Hz, 1H), 6.28–6.26 (d, J = 8.0 Hz, 2H), 3.85–3.82 (m, 2H), 2.57–2.52 (m, 1H), 2.46–2.37 (m, 1H), 2.33–2.18 (m, 2H). 13C-NMR (126 MHz, CDCl3) δ 181.5, 145.3, 139.2, 132.1, 129.0, 128.6, 123.02, 122.99, 117.0, 112.7, 110.8, 69.7, 50.5, 41.8, 23.0. IR νmax (KBr, film, cm−1): 3202, 3092, 3059, 2922, 2851, 1717, 1505, 1469, 746. HRMS (ESI): calcd for C17H15ON2− [M − H]−: 263.1190, found: 263.1191.
1′-Benzylspiro[indoline-3,2′-piperidin]-2-one (2o): White solid, 9.8 mg (from 0.10 mmol), 34% yield, m.p. 167–169 °C. 1H-NMR (500 MHz, CDCl3) δ 7.50 (br, 1H), 7.48–7.46 (d, J = 7.5 Hz, 1H), 7.26–7.25 (m, 4H), 7.23–7.18 (m, 2H), 7.09–7.06 (t, J = 7.5 Hz, 1H), 6.83–6.82 (d, J = 7.5 Hz, 1H), 3.38–3.36 (d, J = 13.0 Hz, 1H), 3.20–3.19 (d, J = 13.0 Hz, 1H), 3.16–3.11 (m, 1H), 2.71–2.67 (m, 1H), 2.11–2.04 (m, 1H), 1.96–1.88 (m, 2H), 1.76–1.72 (m, 1H), 1.69–1.62 (m, 2H). 13C-NMR (101 MHz, CDCl3) δ 180.7, 140.2, 139.4, 133.1, 128.5, 128.4, 128.0, 126.8, 124.1, 122.7, 109.7, 66.3, 56.3, 46.1, 35.3, 25.6, 19.1. IR νmax (KBr, film, cm−1): 3210, 3061, 3028, 2929, 2851, 1702, 1619, 1472, 754. HRMS (ESI): calcd for C19H19ON2− [M−H]−: 291.1503, found: 291.1504.
1-Benzylspiro[azepane-2,3′-indolin]-2′-one (2p): White solid, 4.7 mg (from 0.10 mmol), 15% yield, m.p. 177–179 °C. 1H-NMR (500 MHz, CDCl3) δ 7.67 (s, 1H), 7.62–7.61 (d, J = 7.5 Hz, 1H), 7.32–7.30 (m, 2H), 7.27 (s, 1H), 7.25 (s, 1H), 7.24–7.17 (m, 2H), 7.08–7.05 (t, J = 7.5 Hz, 1H), 6.85–6.83 (d, J = 7.5 Hz, 1H), 3.55–3.50 (dd, J = 15.0, 10.5 Hz, 1H), 3.44–3.42 (d, J = 13.5 Hz, 1H), 3.24–3.21 (d, J = 13.0 Hz, 1H), 2.68–2.64 (dd, J = 15.0, 6.0 Hz, 1H), 2.19–2.05 (m, 2H), 1.92–1.84 (m, 3H), 1.60 (m, 1H) 1.47–1.40 (m, 2H). 13C-NMR (126 MHz, CDCl3) δ 182.4, 140.3, 139.8, 134.8, 128.5, 128.2, 128.0, 126.8, 124.0, 122.7, 109.7, 69.6, 56.5, 47.2, 38.3, 32.4, 30.1, 22.7. IR νmax (KBr, film, cm−1): 3207, 3028, 2925, 2853, 1704, 1651, 1469, 747. HRMS (ESI): calcd for C20H23ON2+ [M + H]+: 307.1805, found: 307.1808.

3.4. Further Functionalization

1′-Benzylspiro[indoline-3,2′-pyrrolidin]-2-one (2a, 0.5 mmol, 139.0 mg) was dissolved in dry THF (10 mL), B2H6 (2.5 mmol, 2.5 mL, 1 M in THF) was added slowly under the Ar. The mixture was heated to reflux for 5 h. And then to the vigorously stirring mixture were added methanol (5 ml) at 0 °C. After being stirred at 0 °C. 10 min, the mixture was warmed to room temperature and reflux for another 30 min. After this time, the solvent was removed under vacuum and residue was purified by silica column chromatography (elute: dichloromethane /methanol 10/1, with 1% NH4OH) to afford the desired product 1′-benzylspiro[indoline-3,2′-pyrrolidine] (3) as an orange solid.
1′-Benzylspiro[indoline-3,2′-pyrrolidine] (3): Orange solid, 70.0 mg (from 0.50 mmol), 53% yield, m.p. 79–81 °C. 1H-NMR (500 MHz, CDCl3) δ 8.14 (s, 1H), 7.59–7.58 (d, J = 7.5 Hz, 1H), 7.31–7.30 (m, 4H), 7.25–7.23 (m, 1H), 7.18–7.15 (t, J = 7.5 Hz, 1H), 7.11–7.09 (t, J = 7.5 Hz, 1H), 6.89 (s, 1H), 3.77 (s, 2H), 2.81–2.78 (t, J = 7.5 Hz, 2H), 2.73 (m, 2H), 2.06 (s, 1H), 1.95–1.92 (t, J = 7.5 Hz, 2H). 13C-NMR (126 MHz, CDCl3) δ 140.2, 136.3, 128.4, 128.2, 127.4, 126.9, 121.8, 121.2, 119.0, 118.8, 116.1, 111.0, 62.5, 53.9, 49.1, 30.2, 30.0, 22.8. IR νmax (KBr, film, cm−1): 3414, 3241, 3057, 2926, 2849, 1456, 1098, 741, 697. HRMS (ESI): calcd for C18H21N2+ [M + H]+: 265.1699, found: 265.1695.

3.5. Control Experiment

3-(3-(Benzylamino)propyl)indolin-2-one (1a, 0.10 mmol, 28.0 mg), TBAI (0.02 mmol, 7.4 mg) and additive (0.1 mmol) was dissolved in toluene (0.5 mL). 35% of H2O2 (0.6 mmol, 52.0 μL) was added and the reaction mixture was stirred at room temperature for 0.5 h. After that time, the mixture was quenched by saturated sodium thiosulfate solution (1 mL) and diluted with dichloromethane (10 mL). The organic layer was washed by water (10 mL × 2), dried over anhydrous sodium sulfate and evaporated to afford the crude product. The crude was purified by silica column chromatography (elute: petroleum ether/ethyl acetate 2/1) to give the pure product 2a.

4. Conclusions

In summary, we have disclosed a new strategy for the construction of spirooxindoles via an intramolecular cyclization through an oxidative C-H/N-H bond coupling process under the catalysis of an iodide/H2O2 system. The representative synthetic examples demonstrate the inherent potential of this metal-free catalytic approach for the preparation of various 3,2′-pyrrolidinyl-spirooxindoles and their 6-/7-membered analogs. Further application of this method for the efficient synthesis of complex chiral 3,2′-pyrrolidinyl-spirooxindole products and other larger fused oxindoles are underway in our laboratory and will be reported in due course.

Supplementary Materials

The following supplementary information are available online: Experimental details, 1H and 13C NMR spectra of starting materials and products, X-Ray structural data for product 2k.

Author Contributions

Conceptualization, L.C. and L.L.; Methodology, D.W.; Investigation, Y.-T.G., X.-Y.J., Q.L. and A.-D.L. Supervision, L.C. and L.L.; Funding Acquisition, L.C. and L.L.

Funding

This work was supported by the National Key R&D Program of China (2016YFA0602900), National Natural Science Foundation of China (21778057, 21502201 and 21420102003), Young Elite Scientist Sponsorship Program by CAST (2015QNRC001) and Chinese Academy of Sciences.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Galliford, C.V.; Scheidt, K.A. Pyrrolidinyl-spirooxindole natural products as inspirations for the development of potential therapeutic agents. Angew. Chem. Int. Ed. 2007, 46, 8748–8758. [Google Scholar] [CrossRef] [PubMed]
  2. Yang, J.; Wearing, X.Z.; Le Quesne, P.W.; Deschamps, J.R.; Cook, J.M. Enantiospecific synthesis of (+)-alstonisine via a stereospecific osmylation process (1). J. Nat. Prod. 2008, 71, 1431–1440. [Google Scholar] [CrossRef] [PubMed]
  3. Trost, B.M.; Brennan, M.K. Asymmetric syntheses of oxindole and indole spirocyclic alkaloid natural products. Synthesis 2009, 18, 3003–3025. [Google Scholar] [CrossRef]
  4. Li, S.M. Prenylated indole derivatives from fungi: Structure diversity, biological activities, biosynthesis and chemoenzymatic synthesis. Nat. Prod. Rep. 2010, 27, 57–58. [Google Scholar] [CrossRef] [PubMed]
  5. Zhou, F.; Liu, Y.L.; Zhou, J. Catalytic asymmetric synthesis of oxindoles bearing a tetrasubstituted stereocenter at the c-3 position. Adv. Synth. Catal. 2010, 352, 1381–1407. [Google Scholar] [CrossRef]
  6. Ball-Jones, N.R.; Badillo, J.J.; Franz, A.K. Strategies for the enantioselective synthesis of spirooxindoles. Org. Biomol. Chem. 2012, 10, 5165–5181. [Google Scholar] [CrossRef] [PubMed]
  7. Hong, L.; Wang, R. Recent advances in asymmetric organocatalytic construction of 3,3′-spirocyclic oxindoles. Adv. Synth. Catal. 2013, 355, 1023–1052. [Google Scholar] [CrossRef]
  8. Cheng, D.; Ishihara, Y.; Tan, B.; Barbas, C.F., III. Organocatalytic asymmetric assembly reactions: Synthesis of spirooxindoles via organocascade strategies. ACS Catal. 2014, 4, 743–762. [Google Scholar] [CrossRef]
  9. Cao, Z.Y.; Zhou, F.; Zhou, J. Development of synthetic methodologies via catalytic enantioselective synthesis of 3,3-disubstituted oxindoles. Acc. Chem. Res. 2018, 51, 1443–1454. [Google Scholar] [CrossRef] [PubMed]
  10. Shi, F.; Xing, G.J.; Zhu, R.Y.; Tan, W.; Tu, S. A catalytic asymmetric isatin-involved povarov reaction: Diastereo- and enantioselective construction of spiro[indolin-3,2′-quinoline] scaffold. Org. Lett. 2013, 15, 128–131. [Google Scholar] [CrossRef] [PubMed]
  11. Yogita, M.; Ragini, G.; Ekta, M. Ultrasound promoted imino diels-alder reaction of ketimine-isatin for the generation of spiro [indoline-3,2-quinoline]-2-onesusing peg 400 as a green solvent andevaluation of their anti-microbial and analgesic activity. Int. J. Res. Chem. Environ. 2015, 5, 106–117. [Google Scholar]
  12. Ghost, A.K.; Schiltz, G.; Perali, R.S.; Leshchenko, S.; Kay, S.; Walters, D.E.; Koh, Y.; Maeda, K.; Mitsuya, H. Design and synthesis of novel HIV-1 protease inhibitors incorporating oxyindoles as the P2′-ligands. Bioorg. Med. Chem. Lett. 2006, 16, 1869–1873. [Google Scholar]
  13. Yeung, B.K.S.; Zou, B.; Rottmann, M.; Lakshminara-yana, S.B.; Ang, S.H.; Leong, S.Y.; Tan, J.; Wong, J.; Keller-Maerki, S.; Fischli, C.; et al. Spirotetrahydro β-carbolines (spiroindolones): A new class of potent and orally efficacious compounds for the treatment of malaria. J. Med. Chem. 2010, 53, 5155–5164. [Google Scholar] [CrossRef] [PubMed]
  14. Kornet, M.J.; Thio, A.P. Oxindole-3-spiropyrrolidines and -piperidines. Synthesis and local anesthetic activity. J. Med. Chem. 1976, 19, 892–898. [Google Scholar] [CrossRef] [PubMed]
  15. Ra-jesh, S.M.; Perumal, S.; Menéndez, J.C.; Yogeeswari, P.; Sriram, D. Antimycobacterial activity of spirooxindolo-pyrrolidine, pyrrolizine and pyrrolothiazole hybrids obtained by a three-component regio- and stereoselective 1,3-dipolar cycloaddition. Med. Chem. Comm. 2011, 2, 626–630. [Google Scholar] [CrossRef]
  16. Gollner, A.; Rudolph, D.; Arnhof, H.; Bauer, M.; Blake, S.M.; Boehmelt, G.; Cockroft, X.L.; Dahmann, G.; Ettmayer, P.; Gerstberger, T.; et al. Discovery of novel spiro[3h-indole-3,2′-pyrrolidin]-2(1h)-one compounds as chemically stable and orally active inhibitors of the mdm2-p53 interaction. J. Med. Chem. 2016, 59, 10147–10162. [Google Scholar] [CrossRef] [PubMed]
  17. Ito, M.; Iwatani, M.; Yamamoto, T.; Kawamoto, T.; Morishita, D.; Nakanishi, A.; Maezaki, H. Discovery of spiro[indole-3,2′-pyrrolidin]-2(1H)-one based inhibitors targeting Brr2, a core component of the U5 snRNP. Bioorg. Med. Chem. 2017, 25, 4753–4767. [Google Scholar] [CrossRef] [PubMed]
  18. Voituriez, A.; Pinto, N.; Neel, M.; Retailleau, P.; Marinetti, A. An organocatalytic [3 + 2] cyclisation strategy for the highly enantioselective synthesis of spirooxindoles. Chem. Eur. J. 2010, 16, 12541–12544. [Google Scholar] [CrossRef] [PubMed]
  19. Gomez, C.; Gicquel, M.; Carry, J.C.; Schio, L.; Retailleau, P.; Voituriez, A.; Marinetti, A. Phosphine-catalyzed synthesis of 3,3-spirocyclopenteneoxindoles from γ-substituted allenoates: Systematic studies and targeted applications. J. Org. Chem. 2013, 78, 1488–1496. [Google Scholar] [CrossRef] [PubMed]
  20. Du, D.; Jiang, Y.; Xu, Q.; Shi, M. Enantioselective construction of spirooxindole derivatives: Asymmetric [3 + 2] cyclization of isothiocyanatooxindoles with allenic esters or 2-butynedioic acid diesters. Adv. Synth. Catal. 2013, 355, 2249–2256. [Google Scholar] [CrossRef]
  21. Zheng, C.G.; Yao, W.J.; Zhang, Y.C.; Ma, C. Chiral spirooxindole-butenolide synthesis through asymmetriC-N-heterocyclic carbene-catalyzed formal (3 + 2) annulation of 3-bromoenals and isatins. Org. Lett. 2014, 16, 5028–5031. [Google Scholar] [CrossRef] [PubMed]
  22. Jiang, D.L.; Dong, S.D.; Tang, W.F.; Lu, T.; Du, D. N-Heterocyclic carbene-catalyzed formal [3 + 2] annulation of α-bromoenals with 3-aminooxindoles: A stereoselective synthesis of spirooxindole γ-butyrolactams. J. Org. Chem. 2015, 80, 11593–11597. [Google Scholar] [CrossRef] [PubMed]
  23. Wang, L.Q.; Yang, D.X.; Li, D.; Liu, X.H.; Zhao, Q.; Zhu, R.R.; Zhang, B.Z.; Wang, R. Catalytic asymmetric [3 + 2] cyclization reactions of 3-isothiocyanato oxindoles and alkynyl ketones via an in situ generated magnesium catalyst. Org. Lett. 2015, 17, 4260–4263. [Google Scholar] [CrossRef] [PubMed]
  24. Du, D.; Jiang, Y.; Xu, Q.; Tang, X.Y.; Shi, M. Enantioselective [3 + 2] cyclization of 3-isothiocyanato oxindoles with trifluoromethylated 2-butenedioic acid diesters. ChemCatChem 2015, 7, 1366–1371. [Google Scholar] [CrossRef]
  25. Feng, B.X.; Yang, J.D.; Li, J.Y. Asymmetric [3 + 2] annulations of 1,4-di-thiane-2,5-diol and oxindole ketimines. Tetrahedron Lett. 2016, 57, 3457–3461. [Google Scholar] [CrossRef]
  26. Du, D.; Jiang, Y.; Xu, Q.; Li, X.G.; Shi, M. Enantioselective synthesis of spirooxindole enols: Regioselective and asymmetric [3 + 2] cyclization of 3-isothiocyanato oxindoles with dibenzylidene ketones. ChemistryOpen 2016, 5, 311–314. [Google Scholar] [CrossRef] [PubMed]
  27. Labroo, R.B.; Labroo, V.M.; King, M.M.; Cohen, L.A. An improved synthesis of dioxindole-3-propionic acid and some transformations of the C-3 hydroxyl group. J. Org. Chem. 1991, 56, 3637–3642. [Google Scholar] [CrossRef]
  28. Liu, R.R.; Xu, Y.; Liang, R.X.; Xiang, B.; Xie, H.J.; Gao, J.R.; Jia, Y.X. Spirooxindole synthesis via palladium-catalyzed dearomative reductive-Heck reaction. Org. Biomol. Chem. 2017, 15, 2711–2715. [Google Scholar] [CrossRef] [PubMed]
  29. Zhang, B.; Zhang, X.; Hu, B.; Sun, D.; Wang, S.; Zhang-Negrerie, D.; Du, Y. PhI(OCOCF3)2-mediated construction of a 2-spiropseudoindoxyl skeleton via cascade annulation of 2-sulfonamido-n-phenylpropiolamide derivatives. Org. Lett. 2017, 19, 902–905. [Google Scholar] [CrossRef] [PubMed]
  30. Collet, F.; Dodd, R.H.; Dauban, P. Catalytic C-H amination: Recent progress and future directions. Chem. Commun. 2009, 45, 5061–5074. [Google Scholar] [CrossRef] [PubMed]
  31. Collet, F.; Lescot, C.; Dauban, P. Catalytic C-H amination: The stereoselectivity issue. Chem. Soc. Rev. 2011, 40, 1926–1936. [Google Scholar] [CrossRef] [PubMed]
  32. Louillat, M.L.; Patureau, F.W. Oxidative C-H amination reactions. Chem. Soc. Rev. 2014, 43, 901–910. [Google Scholar] [CrossRef] [PubMed]
  33. Jiao, J.; Murakami, K.; Itami, K. Catalytic methods for aromatic c-h amination: An ideal strategy for nitrogen-based functional molecules. ACS Catal. 2016, 6, 610–633. [Google Scholar] [CrossRef]
  34. Park, Y.; Kim, Y.; Chang, S. Transition metal-catalyzed c-h amination: Scope, mechanism, and applications. Chem. Rev. 2017, 117, 9247–9301. [Google Scholar] [CrossRef] [PubMed]
  35. Hazelard, D.; Nocquet, P.A.; Compain, P. Catalytic C-H amination at its limits: Challenges and solutions. Org. Chem. Front. 2017, 4, 2500–2521. [Google Scholar] [CrossRef]
  36. Antonchick, A.P.; Samanta, R.; Kulikov, K.; Lategahn, J. Organocatalytic, oxidative, intramolecular c-h bond amination and metal-free cross-amination of unactivated arenes at ambient temperature. Angew. Chem. Int. Ed. 2011, 50, 8605–8608. [Google Scholar] [CrossRef] [PubMed]
  37. Souto, J.A.; Becker, P.; Iglesias, Á.; Muñiz, K. Metal-free iodine (iii)-promoted direct intermolecular c-h amination reactions of acetylenes. J. Am. Chem. Soc. 2012, 134, 15505–15511. [Google Scholar] [CrossRef] [PubMed]
  38. Xue, Q.; Xie, J.; Li, H.; Cheng, Y.; Zhu, C. Metal-free, highly efficient organocatalytic amination of benzylic C-H bonds. Chem. Commun. 2013, 49, 3700–3702. [Google Scholar] [CrossRef] [PubMed]
  39. Kashiwa, M.; Sonoda, M.; Tanimori, S. Facile access to 1h-indazoles through iodobenzene-catalyzed c-h amination under mild, transition-metal-free conditions. Eur. J. Org. Chem. 2014, 4720–4723. [Google Scholar] [CrossRef]
  40. Samanta, S.; Ravi, C.; Rao, S.N.; Joshi, A.; Adimurthy, S. Visible-light-promoted selective C-H amination of heteroarenes with heteroaromatic amines under metal-free conditions. Org. Biomol. Chem. 2017, 15, 9590–9594. [Google Scholar] [CrossRef] [PubMed]
  41. Xin, J.R.; He, Y.H.; Guan, Z. Metal-free aerobic oxidative direct C-H amination of electron-deficient alkenes via photoredox catalysis. Org. Chem. Front. 2018, 5, 1684–1688. [Google Scholar] [CrossRef]
  42. Uyanik, M.; Ishihara, K. In situ-generated chiral quaternary ammonium (hypo)iodite catalysis for enantioselective oxidative cyclizations. Chim. Oggi 2011, 29, 18–21. [Google Scholar] [CrossRef]
  43. Uyanik, M.; Ishihara, K. Catalysis with in situ-generated (hypo)iodite ions for oxidative coupling reactions. ChemCatChem 2012, 4, 177–185. [Google Scholar] [CrossRef]
  44. Wang, L.L.; Bai, J.F.; Peng, L.; Qi, L.W.; Jia, L.N.; Guo, Y.L.; Luo, X.Y.; Xu, X.Y.; Wang, L.X. Organocatalytic stereocontrolled synthesis of 3,3′-pyrrolidinyl spirooxindoles by [3 + 2] annulation of isocyanoesters with methyleneindolinones. Chem. Commun. 2012, 48, 5175–5177. [Google Scholar] [CrossRef] [PubMed]
  45. Finkbeiner, P.; Nachtsheim, B.J. Iodine in modern oxidation catalysis. Synthesis 2013, 45, 979–999. [Google Scholar]
  46. Wu, X.F.; Gong, J.L.; Qi, X. A powerful combination: Recent achievements on using TBAI and TBHP as oxidation system. Org. Biomol. Chem. 2014, 12, 5807–5817. [Google Scholar] [CrossRef] [PubMed]
  47. Liu, D.; Lei, A. Iodine-catalyzed oxidative coupling reactions utilizing c-h and x-h as nucleophiles. Chem. Asian J. 2015, 10, 806–823. [Google Scholar] [CrossRef] [PubMed]
  48. Majji, G.; Rout, S.K.; Rajamanickam, S.; Guin, S.; Patel, B.K. Synthesis of esters via sp3 C-H functionalization. Org. Biomol. Chem. 2016, 14, 8178–8211. [Google Scholar] [CrossRef] [PubMed]
  49. García-Mateos, F.J.; Imane Moulefera, I.; Rosas, J.M.; Benyoucef, A.; Rodríguez-Mirasol, J.; Cordero, T. Alcohol dehydrogenation on kraft lignin-derived chars with surface basicity. Catalysts 2017, 7, 308. [Google Scholar] [CrossRef]
  50. Chen, R.X.; Chen, J.J.; Zhang, J.; Wan, X.B. Design and synthesis of powerful capsule catalysts aimed at applications in c1 chemistry and biomass conversion. Chem. Rec. 2018, 18. [Google Scholar] [CrossRef]
  51. Yadav, V.K.; Srivastava, V.P.; Yadav, L.D.S. Iodide catalyzed synthesis of 2-aminobenzoxazoles via oxidative cyclodesulfurization of phenolic thioureas with hydrogen peroxide. Tetrahedron Lett. 2018, 59, 252–255. [Google Scholar] [CrossRef]
  52. Wei, F.; Huang, H.Y.; Zhong, N.J.; Gu, C.L.; Wang, D.; Liu, L. Highly enantioselective [3 + 2]-annulation of isatin-derived morita-baylis-hillman adducts with cyclic sulfonimines. Org. Lett. 2015, 17, 1688–1691. [Google Scholar] [CrossRef] [PubMed]
  53. Huang, H.Y.; Wu, H.R.; Wei, F.; Wang, D.; Liu, L. Iodine-catalyzed direct olefination of 2-oxindoles and alkenes via cross-dehydrogenative coupling (cdc) in air. Org. Lett. 2015, 17, 3702–3705. [Google Scholar] [CrossRef] [PubMed]
  54. Wu, H.R.; Huang, H.Y.; Ren, C.L.; Liu, L.; Wang, D.; Li, C.J. FeIII-Catalyzed cross-dehydrogenative arylation (cda) between oxindoles and arenes under an air atmosphere. Chem. Eur. J. 2015, 21, 16744–16748. [Google Scholar] [CrossRef] [PubMed]
  55. Wei, F.; Cheng, L.; Huang, H.Y.; Liu, J.J.; Wang, D.; Liu, L. Intermolecular dearomative oxidative coupling of indoles with ketones and sulfonylhydrazines catalyzed by I2: Synthesis of [2,3]-fused indoline tetrahydropyridazines. Sci. China Chem. 2016, 59, 1311. [Google Scholar] [CrossRef]
  56. Kong, D.L.; Cheng, L.; Yue, T.; Wu, H.R.; Feng, W.C.; Wang, D.; Liu, L. Cobalt-catalyzed peroxidation of 2-oxindoles with hydroperoxides. J. Org. Chem. 2016, 81, 5337–5344. [Google Scholar] [CrossRef] [PubMed]
  57. Huang, H.Y.; Cheng, L.; Liu, J.J.; Wang, D.; Liu, L.; Li, C.J. Transition-metal-free alkynylation of 2-oxindoles through radical-radical coupling. J. Org. Chem. 2017, 82, 2656–2663. [Google Scholar] [CrossRef] [PubMed]
  58. Chen, G.; He, H.P.; Ding, J.; Hao, X.J. Synthesis and antitumor activity evaluation of regioselective spiro [pyrrolidine-2,3′-oxindole] compounds. Heterocycl. Comm. 2009, 15, 355–360. [Google Scholar] [CrossRef]
  59. Puleo, L.; Marini, P.; Avallone, R.; Zanchet, M.; Bandi-era, S.; Baroni, M.; Croci, T. Synthesis and pharmacological evaluation of indolinone derivatives as novel ghrelin receptor antagonists. Bioorg. Med. Chem. 2012, 20, 5623–5636. [Google Scholar] [CrossRef] [PubMed]
  60. Huang, H.; Chen, W.H.; Xu, Y.; Li, J. I−/TBHP catalyzed Csp3-N/Csp2-N bond formation via oxidative coupling with benzophenone imine in water. Green Chem. 2015, 17, 4715–4719. [Google Scholar] [CrossRef]
  61. Satoshi Mizuta, S.; Otaki, H.; Kitagawa, K.; Morii, K.Y.; Ishihara, J.; Ni-shi, K.; Hashimoto, R.; Usui, T.; Chiba, K. Ionic liquid-mediated hydrofluorination of o-azaxylylenes derived from 3-bromooxindoles. Org. Lett. 2017, 19, 2572–2575. [Google Scholar] [CrossRef] [PubMed]
  62. Wei, W.T.; Zhu, W.M.; Bao, W.H.; Chen, W.T.; Huang, Y.L.; Gao, L.H.; Xu, X.D.; Wang, Y.M.; Chen, G.P. Metal-free c(sp3)-h amination of 2-oxindoles in water: Facile synthesis of 3-substituted 3-aminooxindoles. ACS Sustain. Chem. Eng. 2018, 6, 5615–5619. [Google Scholar] [CrossRef]
  63. Karthikeyan, S.V.; Bala, B.D.; Raja, V.P.; Perumal, S.; Yogees-wari, P.; Sriram, D. A highly atom economic, chemo-, regio- and stereoselective synthesis and evaluation of spiro-pyrrolothiazoles as antitubercular agents. Bioorg. Med. Chem. Lett. 2010, 20, 350–353. [Google Scholar] [CrossRef] [PubMed]
  64. Li, G.; Huang, L.; Xu, J.; Sun, W.; Xie, J.; Hong, L.; Wang, R. Sodium iodide/hydrogen peroxide-mediated oxidation/lactonization for the construction of spirocyclic oxindole-lactones. Adv. Synth. Catal. 2016, 358, 2873–2877. [Google Scholar] [CrossRef]
  65. Ohmatsu, K.; Ando, Y.; Nakashima, T.; Ooi, T. A modular strategy for the direct catalytic asymmetric α-amination of carbonyl compounds. Chem 2016, 1, 802. [Google Scholar] [CrossRef]
  66. Luo, J.F.; Wei, W.T. Recent Advances in the construction of C-N bonds through coupling reactions between carbon radicals and nitrogen radicals. Adv. Synth. Catal. 2018, 360, 2076–2086. [Google Scholar] [CrossRef]
  67. Ooi, T.; Maruoka, K. Recent advances in asymmetric phase-transfer catalysis. Angew. Chem. Int. Ed. 2007, 46, 4222–4266. [Google Scholar] [CrossRef] [PubMed]
  68. Uyanik, M.; Okamoto, H.; Yasui, T.; Ishihara, K. Quaternary ammonium (hypo)iodite catalysis for enantioselective oxidative cycloetherification. Science 2010, 328, 1376–1379. [Google Scholar] [CrossRef] [PubMed]
  69. Uyanik, M.; Hayashi, H.; Ishihara, K. High-turnover hypoiodite catalysis for asymmetric synthesis of tocopherols. Science 2014, 345, 291–294. [Google Scholar] [CrossRef] [PubMed]
  70. Martin, D.B.C.; Nguyen, L.Q.; Vanderwal, C.D. Syntheses of strychnine, norfluorocurarine, dehydrodesacetylretuline, and valparicine enabled by intramolecular cycloadditions of zincke aldehydes. J. Org. Chem. 2012, 77, 17–46. [Google Scholar] [CrossRef] [PubMed]
  71. Cashion, D.; Mortensen, D.; Cashion, D.; Mortensen, D.; Huang, D.H.; Torres, E.; Parens, J.; Sapienza, J.; Hansen, J.; Leftheris, K.; et al. Substituted Diaminopyrimidyl Compouns, Compositions Thereof, and Methods of Treatment Therewith. WO2015095679, 25 June 2015. [Google Scholar]
Sample Availability: Samples of the compounds 2a–n are available from the authors.
Molecules 23 02265 g001 550
Figure 1. Biologically active 3,2′-pyrrolidinyl spirooxindole derivatives
Figure 1. Biologically active 3,2′-pyrrolidinyl spirooxindole derivatives
Molecules 23 02265 g001
Molecules 23 02265 sch001 550
Scheme 1. Strategies for the 3,2′-pyrrolidinyl spirooxindole synthesis.
Scheme 1. Strategies for the 3,2′-pyrrolidinyl spirooxindole synthesis.
Molecules 23 02265 sch001
Molecules 23 02265 sch002 550
Scheme 2. Investigations on the substrate scope.
Scheme 2. Investigations on the substrate scope.
Molecules 23 02265 sch002
Molecules 23 02265 sch003 550
Scheme 3. Selective reduction of the cyclization product.
Scheme 3. Selective reduction of the cyclization product.
Molecules 23 02265 sch003
Molecules 23 02265 sch004 550
Scheme 4. Control experiments.
Scheme 4. Control experiments.
Molecules 23 02265 sch004
Molecules 23 02265 sch005 550
Scheme 5. The proposed mechanism.
Scheme 5. The proposed mechanism.
Molecules 23 02265 sch005
Molecules 23 02265 sch006 550
Scheme 6. Preliminary experiments applying chiral iodide catalysts.
Scheme 6. Preliminary experiments applying chiral iodide catalysts.
Molecules 23 02265 sch006
Table
Table 1. Studies and optimization of the reaction paramaters1.
Table 1. Studies and optimization of the reaction paramaters1.
Molecules 23 02265 i001
Entry[I]OxidantSolventTemp. (°C)Yield (%) 2
1 2,3TBAITBHPH2O6041 4
2 2,3I2TBHPH2O6033 5
3NaITBHPH2ORT56 4
4NaIH2O2CH3CNRT58 4
5TBAIH2O2CH3CNRT62 4
6TBAIH2O2H2ORT33 4
7TBAIH2O2MeOHRT56 6
8TBAIH2O2THFRT64 6
9 2,7TBAIH2O2TolueneRT79
1 Unless noted otherwise, all the reactions were conducted with 3-(3-(benzylamino)-propyl)-2-oxindole (1a, 0.1 mmol), catalyst (0.01 mmol), oxidant (6.0 equiv.) in the indicated solvent (1 mL) for 30 min. Isolated yields are given. 2 Catalyst loading: 20 mol·%. 3 Oxidant amount: 2.0 equiv. 4 Reaction time: 5 h. 5 Reaction time: 4 h. 6 Reaction time: 3.5 h. 7 Solvent volume: 0.5 mL.

Share and Cite

MDPI and ACS Style

Gao, Y.-T.; Jin, X.-Y.; Liu, Q.; Liu, A.-D.; Cheng, L.; Wang, D.; Liu, L. Iodide/H2O2 Catalyzed Intramolecular Oxidative Amination for the Synthesis of 3,2′-Pyrrolidinyl Spirooxindoles. Molecules 2018, 23, 2265. https://doi.org/10.3390/molecules23092265

AMA Style

Gao Y-T, Jin X-Y, Liu Q, Liu A-D, Cheng L, Wang D, Liu L. Iodide/H2O2 Catalyzed Intramolecular Oxidative Amination for the Synthesis of 3,2′-Pyrrolidinyl Spirooxindoles. Molecules. 2018; 23(9):2265. https://doi.org/10.3390/molecules23092265

Chicago/Turabian Style

Gao, Yu-Ting, Xiao-Yang Jin, Qi Liu, An-Di Liu, Liang Cheng, Dong Wang, and Li Liu. 2018. "Iodide/H2O2 Catalyzed Intramolecular Oxidative Amination for the Synthesis of 3,2′-Pyrrolidinyl Spirooxindoles" Molecules 23, no. 9: 2265. https://doi.org/10.3390/molecules23092265

Article Metrics

Back to TopTop